| | | |

Could This Protein Play a Role in Survival of Pleural Mesothelioma?

ByAlex Strauss
Survival of pleural mesothelioma could depend on this protein

Research funded by the National Cancer Institute has identified a protein that might play a key role in survival of pleural mesothelioma. 

The protein is called UHRF1. It is encoded by a gene of the same name. Researchers believe it may be a driver of growth and spread in malignant mesothelioma. 

The research will have to be confirmed on a larger scale. But if it turns out to be true, it could give doctors a new way to extend survival of pleural mesothelioma. 

Finding Drivers of Mesothelioma Growth

Pleural mesothelioma is a membrane (mesothelium) cancer caused by asbestos exposure. Although some people do survive mesothelioma, it is rare. Average survival of pleural mesothelioma is right around 18 months. 

It can take decades for mesothelioma to develop after asbestos exposure. Once it does, it typically grows and spreads quickly. Researchers are still trying to understand why this is. If they can isolate drivers of mesothelioma growth, they may be able to slow it down. 

According to the NCI scientists, the UHRF1 protein “has emerged as an epigenetic driver in human cancers”.  Epigenetic means a non-genetic influence on gene expression. The goal of the new study was to determine whether UHRF1 impacts survival of pleural mesothelioma as it seems to with other cancers. If it does, the next step will be to find ways to regulate it. 

Increasing Survival of Pleural Mesothelioma

Researchers started by measuring the UHRF1 level in different kinds of cells.  They analyzed UHRF1 in 

  • normal mesothelial cells 
  • asbestos-exposed mesothelial cells 
  • lab-grown pleural mesothelioma cells lines 
  • normal pleural membrane cells 
  • cells from pleural mesothelioma patients

“UHRF1 expression was significantly higher in malignant pleural mesothelioma lines and specimens,” states the report in the Journal of Thoracic Oncology. Even the normal mesothelioma cells had higher levels of UHRF1 after asbestos exposure. 

Even more importantly, patients with higher UHRF1 had shorter survival of pleural mesothelioma. “The overexpression of UHRF1 was associated with decreased overall survival in patients with MPM,” writes NCI researcher David Schrump.  

Researchers experimented with different ways to knock down UHRF1 expression. The chemotherapy drug mithramycin reduced UHRF1 in lab-grown cells and in mice that were infected with pleural mesothelioma. Drugs that raised levels of the tumor suppressor protein p53 also reduced UHRF1. 

The researchers concluded that UHRF1 helps mesothelioma tumors grow and that reducing it could improve survival in pleural mesothelioma. 

“These findings support the efforts to target UHRF1 expression or activity for mesothelioma therapy,” the study concludes. 

Sources:

Reardon, E, et al, “UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma”, September 11, 2020, Journal of Thoracic Oncology, Epub ahead of print, https://www.jto.org/article/S1556-0864(20)30716-4/fulltext

Moench, S, “UHRF1 May Be an Actionable Target in Malignant Pleural Mesothelioma”, October 8, 2020, Cancer Therapy Advisor, https://www.cancertherapyadvisor.com/home/cancer-topics/lung-cancer/mesothelioma-uhrf1-actionable-target-treatment/

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…